GB-263 is under clinical development by Genor BioPharma and currently in Phase II for Head And Neck Cancer Squamous Cell Carcinoma. According to GlobalData, Phase II drugs for Head And Neck Cancer Squamous Cell Carcinoma have a 26% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how GB-263’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

GB-263 overview

GB-263 is under development for the treatment of non-small cell lung cancer, gastric cancer, esophageal cancer, head and neck squamous cell carcinoma, metastatic colorectal cancer and other solid tumors. It is administered through intravenous as an injection. It is a tri-specific monoclonal antibody, acts by targeting epidermal growth factor receptor (EGFR) and hepatocyte growth factor receptor (c Met) (EGFR/cMET/cMET).

Genor BioPharma overview

Genor Biopharma, a subsidiary of HH CT Holdings Ltd, is a biopharmaceutical company which develops and commercializes drugs to treat oncology and autoimmune diseases. The company is investigating GB491, an oral CDK4/6 inhibitor targeting metastatic and early breast cancer; GB221, a monoclonal antibody for the treatment of HER2+ breast cancer and solid tumors; GB226 monotherapy against cervical and other cancer indications; and GB492, a STING agonist targeting solid tumors. It is also developing GB242, a chimeric monoclonal antibody against rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn´s disease, and ulcerative colitis; and GB223, a RANKL (receptor activator of NF-kappaB ligand) monoclonal antibody to treat giant-cell tumor of bone (GCTB). Genor Biopharma is headquartered in Shanghai, China.

For a complete picture of GB-263’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.